Hematologic investigations: Morphologic and phenotypic features of myeloma marrow diagnosis

Multiple Myeloma and Related Disorders

Volumn , Issue , 2004, Pages 102-124

  Grogan, Thomas M ^a   Gelbspan, Deborah ^a   Rimsza, Lisa ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751584291     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (109)

1. Buss DH, Prichard RW, Hartz JW, Cooper MR, Feigin GA. Initial bone marrow findings in multiple myeloma. Significance of plasma cell nodules. Arch Pathol Lab Med 1986; 110:30-3.
2. Zucker-Franklin D. The pathology of multiple myeloma and related disorders. In Wiernik P, Cannellos, Kyle R, Schiffer C (eds) Neoplastic diseases of the blood. New York: Churchill Livingstone, 1985:462.
3. Bartl R, Frisch B, Burkhardt R, Fateh-Moghadam A, Mahl G, Gierster P, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging: Br J Haematol 1982; 51:361-75.
4. Grogan TM, Spier CM. The B cell immunoproliferative disorders including multiple myeloma and amyloidosis. In Knowles DM (ed.) Neoplastic hematopathology, 2nd edn. Philadelphia: Lippincott, Williams and Wilkins, 2001:1235-66.
5. Fritz E, Ludwig H, Kundi M. Prognostic relevance of cellular morphology in multiple myeloma. Blood 1984; 63:1072-9.
6. Greipp R, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65:305-10.
7. Azar HA. Pathology of multiple myeloma. In Azar HA, Potter M (eds) Multiple myeloma and related disorders, Vol. 1. New York: Harper and Row, 1973:5.
8. Greipp PR, Kyle RA. Clinical morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood 1983; 62:166-71.
9. Farquhar MG, Palade GE. The golgi apparatus (1954-1981) from artifact to center stage. J Cell Biol 1981; 91(Suppl):77-103.
10. Maldonado JE, Brown AL Jr, Bayrd ED, Pease GL. Cytoplasmic and intranuclear electron-dense bodies in the myeloma cell. Arch Pathol 1966; 81:484-500.
11. Pavelta M, Ludwig H. Ultrastructural studies of myeloma cells: observations concerning the golgi apparatus and intermediate-size filaments. Am J Hematol 1983; 15:237-51.
12. Blom J, Mansa B, Wiik A. A study of Russell bodies in human monoclonal plasma cells by means of immunofluorescence and electron microscopy. Acta Pathol Microbiol Scand 1976; 84A:335-49.
13. Maldonado JE, Bayrd ED, Brown AL Jr. The flaming cell in multiple myeloma. A light and electron microscopy study. Am J Clin Pathol 1965; 44:605-12.
14. Jandl J. Multiple myeloma and other differentiated B cell malignancies. In Blood: textbook of hematology. Boston: Little Brown & Co, 1987:831.
15. Bergsagel DE. Plasma cell myeloma. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA (eds) Hematology, 3rd edn. New York: McGraw-Hill, 1983:831.
16. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In Hoffbrand AV, Brian MC, Hirsh J (eds) Recent advances in hematology. Edinburgh: Churchill Livingstone, 1977:243.
17. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13:300-9.
18. Salmon SE, Cassady JR: Plasma cell neoplasms. In DeVita VT, Hellman S, Rosenberg S (eds) Cancer, principles and practice of oncology. Philadelphia: J.B. Lippincott, 1988:1864.
19. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001; 68:269-75.
20. Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffinembedded bone marrow biopsy specimens. Hum Pathol 1999; 30:1405-11.
21. Anderson KC, Bates MP, Slaughenhoupt B, Schlossman SF, Nadler LM. A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol 1984; 132:3172-9.
22. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 2001; 4:1052-8.
23. Ling NR, MacLennan ICM, Mason DY. B-cell and plasma cell antigens: new and previously defined clusters. In McMichael AJ, Beverley PCL, Cobbold S, Crumpton MJ, Gilka W. (eds) Leukocyte typing III: white cell differentiation antigens. Oxford: Oxford University Press, 1987:302-35.
24. San Miguel JF, Caballero MD, Gonzalez M, Zola H, Lopez Borrasca A. Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. Br J Haematol 1986; 62:75-83.
25. Harada H, Kawano M, Huang N, et al. A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81:2658-63.
26. Barker H, Hamilton M, Ball J, Drew M, Franklin IM. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol 1992; 81:331-5.
27. Ridley R, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type 1 collagen. Blood 1993; 81:767-74.
28. Rawstron AC, Fenton JA, Ashcroft J, English A, Jones RA, Richards SJ, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000; 96:3880-6.
29. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti Tdetects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95:2084-92.
30. Lima M, Teixeira MA, Fonseca S, Goncalves C, Guerra M, Queiros ML, et al. Immunophenotypic aberrations, DNA content and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. Blood Cells Mol Dis 2000; 26:634-45.
31. Mahmoud MS, Huang N, Nobuyoshi M, Lisukou IA, Tanaka H, Kawana MM. Altered expression of PaX-5 gene in human myeloma cells. Blood 1996; 87:4311-15.
32. Kubagawa J, Vogler LB, Capra JD, et al. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med 1979; 150:792-807.
33. Van Riet I, Vanderkerken K, De Greef C, Van Camp. Homing behaviour of the malignant cell clone in multiple myeloma. Med Oncol 1998; 15:1554-64.
34. Ruiz-Arüelles GJ, Katzmann JA, Greipp PR, Gouchoroff NJ, Garton JP, Kyle RA. Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood 1984; 64:352-6.
35. Durie BGM, Grogan TM. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood 1985; 66:229-32.
36. Caligaris-Cappio F, Berui L, Tesio L, et al. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest 1985; 76:1243-51.
37. Epstein J, Barlogie B, Katzmann J, Alexanian R. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood 1988; 71:861-5.
38. Grogan TM, Durie BGM, Lomen C, Spier C, Wirt DP, Nagle R, et al. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture and kinetic features. Blood 1987; 70:932-42.
39. Pilarski LM, Mant MJ, Reuther BA. Pre-B cells in peripheral blood of multiple myeloma patients. Blood 1985; 66:416-22.
40. Grogan TM, Durie BGM, Spier CM, Richter L, Vela E. Myelomonocytic antigen positive multiple myeloma. Blood 1989; 73:763-9.
41. Epstein J, Xiao H, He X-Y. Markers of multiple hematopoietic cell lineages in multiple myeloma. N Engl J Med 1990; 322:664-8.
42. Brown G, Bunce CM, Howie AJ, Lord JM. Stochastic or ordered lineage commitment during hemopoiesis, editorial. Leukemia 1987; 2:150-3.
43. Spier CS, Grogan TM, Durie BGM, et al. T cell antigenpositive multiple myeloma. Mod Pathol 1990; 3:302-7.
44. Buchsbaum RJ, Schwartz RS. Cellular origins of hematologic neoplasms. N Engl J Med 1990; 322:694-6.
45. Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP, et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 1998; 4:1521-6.
46. Dalton WS, Grogan T, Rybski J, Scheper RJ, Richter L, Kailey J, et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73:747-52.
47. Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using 3 antibodies. Lab Invest 1990; 63:815-24.
48. Grogan T, Spier C, Salmon S, Matzner M, Rybski J, Weinstein RS, et al. P-Glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81:490-5.
49. Durie BGM, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988; 68:203-6.
50. Wyler B, Shao Y, Schneider E, Cianfriglia M, Scheper RJ, Frey BM, et al. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. Br J Haematol 1997; 97:65-75.
51. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, et al. Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1990; 7:415-24.
52. Miller TP, Grogan TM, Dalton WS, Spier CS, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9:17-24.
53. Rimsza L, Dalton W, Campbell K, Salmon S, Grogan T. In multiple myeloma the non-P-glycoprotein multidrug resistance protein LRP is frequently expressed and an increased proliferative rate (Ki67 > 5%) is associated with a significantly shorter survival. Leuk Lymphoma 1999; 10:123-6.
54. Filipits M, Drach J, Pohl G, Schuster J, Stranzl T, Ackermann J, et al. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999; 5:2426-30.
55. Gratzner H. Monoclonal antibody to 5-bromo-and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982; 218:474-5.
56. Dolbeare F, Gratzner H, Pallavicini M, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983; 80:5573-7.
57. Durie BGM, Salmon SE. Staging, kinetics and flow cytometry of multiple myeloma. In Wiernik P, Cannellos, Kyle R, Schiffer C (eds) Neoplastic diseases of the blood. New York: Churchill Livingstone, 1985:513.
58. Gerdes J, Dallenbach F, Lennert K. Growth fractions in malignant non-Hodgkin’s lymphomas (NHL) as determined in situ with the monoclonal antibody Ki67. Hematol Oncol 1984; 2:365-71.
59. Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski J, Rangel CS, et al. Independent prognostic significance of a nuclear proliferative antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki67. Blood 1988; 71:1157-60.
60. Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, et al. Immunohistochemical analysis of ayclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000; 156:1505-13.
61. Wilson CS, Butch AW, Lai R, Medeiros LJ, Sawyer JR, Barlogie B, McCourty A, et al. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br J Haematol 2001; 112:776-82.
62. Hoyer JD, Hanson CA, Foneseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Hematopathology t(11:14)(q13:q32) in multiple myeloma. Am J Clin Pathol 2000; 113:831-7.
63. Tosi P, Pellacani A, Visani G, Ottaviani E, Ronconi S, Zamagri E, et al. In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. Eur J Haematol 1999; 62:143-8.
64. Landowski T, Gleason-Guzman M, Dalton W. Selection for drug resistance to fas-mediated apoptosis. Blood 1997; 89:1854-61.
65. Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumorinduced suppression of immune surveillance. Blood 1997; 90:12-20.
66. Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L upregulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 2001; 97:1155-64.
67. Lynch RG, Rohrer JM, Odermatt B, Gebel M, Autry JR, Hoover RG. Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. Immunol Rev 1979; 48:45-80.
68. Broder S, Humphrey R, Durm M, Blackman M, Meade B, Goldman C, et al. Impaired synthesis of polyclonal (nonparaprotein) immunoglobulin by circulating lymphocytes from patients with multiple myeloma: role of suppressor cells. N Engl J Med 1975; 293:887-92.
69. Dianzani U, Pileri A, Boccadoro M, Palumbo S, Massaia M. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988; 72:1064-8.
70. Rai Takari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M, et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T-cells. Br J Haematol 2000; 110:203-9.
71. Kronland R, Grogan T, Spier C, Wirt D, Rangel C, Richter L, et al. Immunotopographic assessment of lymphoid and plasma cell malignancies in the bone marrow. Hum Pathol 1985; 16:1247-54.
72. Xagoraris I, Paterakis G, Zolota B, Zikos P, Maniatis A, Mouzaki A. Expression of granzyme B and d perforin in multiple myeloma. Acta Hematol 2001; 105:125-9.
73. Besostri B, Beggiato E, Bianchi A, Mariani S, Coscia M, Peola S, et al. Increased expression of non-functional killer inhibitory receptor CD94 in CD8 cells of myeloma patients. Br J Haematol 2000; 109:46-53.
74. Stauder R, Van Driel M, Schwarzler C, Thaler J, Lokhorst HM, Kreuser ED, et al. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood 1996; 88:3101-8.
75. Van Camp B, Durie BGM, Spier C, De Wacle M, Van Riet I, Vela E, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu 19). Blood 1990; 76:377-82.
76. Drach J, Gattringer C, Huber H. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol 1991; 83:418-22.
77. Ong F, Kaiser U, Seelen P, Hermans J, Wijermans P, Kieviet W, et al. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes. Blood 1996; 87:712-16.
78. Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard M, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12:1977-82.
79. Van Driel M, Gunthert U, Stauder R, Joling P, Lokhorst H, Bloem A. CD44 isoforms distringuish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease. Leukemia 1998; 12:1821-8.
80. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-63.
81. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79:451-5.
82. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111-16.
83. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol 2001; 28:543-50.
84. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001; 28:551-9.
85. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95:2630-6.
86. Vacca A, Frigeri A, Ribatti D, Nicchia GP, Nico B, Ria R, et al. Miccrovessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. Br J Haematol 2001; 113:415-21.
87. Bellamy W, Richter L, Frutiger Y, Grogan T. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59:728-33.
88. Barlogie B, Latreille J, Swartzenchuber D, et al. Quantitative cytology in myeloma research. In Salmon SE (ed.) Clinics in hematology. London: Saunders, 1982:19.
89. Berenson J, Wong R, Kim K, Brown N, Lichtenstein A. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987; 70:1550-3.
90. Omede P, Boccadoro M, Gallone G, Frieri R, Battaglio S, Redoglia V, et al. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 1990; 76:1375-9.
91. Mellstedt H, Hammarström S, Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol 1974; 17:371-84.
92. Bast E, Van Camp B, Reynaert P, Wiringa G, Ballieux R. Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol 1982; 47:677-82.
93. Ruiz-Arüelles GJ, Katzmann JA, Greipp PR, Gouchoroff NJ, Garton JP, Kyle RA. Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood 1984; 64:352-6.
94. Ullrich S, Zolla-Pazner S. Immunoregulatory circuits in myeloma. In Hoffbrand AV, Lasch HG, Nathan DG, Salmon SE (eds) Clinics in haematology, Vol. 11. Eastbourne: WB Saunders, 1982:87-111.
95. Rawstron AC, Barrans SL, Blythe D, English A, Richards SJ, Fenton JAL, et al. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. Br J Haematol 2001; 113:794-802.
96. Delschlaegel U, Freund D, Range U, Ehninger G, Nowak R. Flow cytometric DNA-quantification of three-color immunophenotyped cells for subpopulation specific determination of aneoploidy and proliferation. J Immunol Meth 2001; 253:145-52.
97. Alexanian R. Localized and indolent myeloma. Blood 1980; 56:521-5.
98. Kyle RA, Greipp R. Smouldering multiple myeloma. N Engl J Med 1980; 302:1347-9.
99. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of the bone. J Clin Oncol 1983; 1:255-62.
100. Kyle RA. Monoclonal gammopathy of undetermined significance (MGUS): a review. In Hoffbrand AV, Lasch HG, Nathan DG, Salmon SE (eds) Clinics in haematology, Vol. 11. Eastbourne: WB Saunders, 1982:123-50.
101. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978; 64:814-26.
102. Salmon S, Cassady JR. Plasma cell neoplasms. In DeVita VT, Hellman S, Rosenberg S (eds) Cancer, principles and practice of oncology. Philadelphia: J.B. Lippincott, 1988:1862.
103. Azar HA. Pathology of multiple myeloma. In Azar HA, Potter M (eds) Multiple myeloma and related disorders, Vol. 1. New York: Harper and Row, 1973:8.
104. Bergsagel DE. Plasma cell myeloma. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA (eds) Hematology, 3rd edn. New York: McGraw-Hill, 1983:1090.
105. Bergsagel DE. Plasma cell myeloma. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA (eds) Hematology, 3rd edn. New York: McGraw-Hill, 1983:1089.
106. Isobe T, Osserman EF. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann NY Acad Sci 1972; 190:507-18.
107. Williams RC, Bailly RC, Howe RB. Studies of ‘benign’ serum M-components. Am J Med Sci 1969; 257:275-93.
108. Azar HA. Pathology of multiple myeloma. In Azar HA, Potter M (eds) Multiple myeloma and related disorders, Vol. 1. New York, Harper and Row, 1973:10.
109. Kapadia S, Desai U, Cheng U. Extramedullary plasmacytoma of the head and neck: a clinicopathologic study of 20 cases. Medicine 1982; 61:317-29.